Jade Biosciences, Inc. 8-K

What Happened
Jade Biosciences announced interim results from its Phase 1 healthy-volunteer trial of JADE101, an investigational anti-APRIL monoclonal antibody for IgA nephropathy (IgAN). As of the April 14, 2026 data cutoff, 32 healthy adults were enrolled across four single‑dose subcutaneous cohorts (175 mg, 350 mg, 700 mg, 1,400 mg; 6:2 randomization to active:placebo). At the 700 mg dose, mean IgA reductions reached approximately 70% from baseline and were sustained at 12 weeks. The company held a webcast and presentation on June 1, 2026 (slides filed as Exhibit 99.1).

Key Details

• Phase 1 design: double‑blind, placebo‑controlled single ascending dose study; 32 participants across four cohorts (175/350/700/1,400 mg). Data cutoff April 14, 2026.
• Efficacy/PD: ~70% mean IgA reduction at 700 mg sustained to 12 weeks; simulated >70% steady‑state IgA reduction with a 700 mg induction then 350 mg every 12 weeks (Q12W). JADE101 achieved rapid, complete and durable suppression of free APRIL.
• Safety: single subcutaneous doses up to 1,400 mg were well tolerated; no serious adverse events or discontinuations; most common treatment‑emergent AEs were headache (25%) and URTI (21.9%); no cases of hypogammaglobulinemia (IgG ≤3 g/L).
• Pharmacokinetics/potential differentiators: JADE101’s IgA‑lowering potency estimated ~379× greater than sibeprenlimab and ~26× greater than povetacicept; reported half‑life ≈8.7× longer than povetacicept and ≈2.6× longer than sibeprenlimab.

Why It Matters
For investors, these interim healthy‑volunteer data highlight JADE101’s strong pharmacodynamic effect (large, durable IgA reductions) and a favorable early safety profile—attributes that could support a convenient infrequent dosing regimen (potentially four injections/year) if replicated in patients. Jade is already running an open‑label Phase 2 (JUNIPER, ~30 patients; 700 mg induction then 350 mg maintenance Q8W or Q12W) and plans a registrational Phase 3 trial in the first half of 2027 pending FDA requirements. These are early, non‑patient results and the company notes interim data and modeled projections may not predict final clinical outcomes; further patient data and regulatory review will determine clinical and commercial prospects.